Lipoflex Special Without Electrolytes

Valine, Alanine, Arginine, Histidine, Isoleucine, Leucine, Methionine, Phenylalanine, Proline and Serine, the active ingredients in Lipoflex Special Without Electrolytes, are an amino acid solution presented as an intravenous solution for intravenous use. It provides essential amino acids to support protein synthesis and metabolic needs in patients who cannot receive enteral nutrition, especially in critical care settings.

GNH USA supplies Lipoflex Special Without Electrolytes as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and clinics worldwide and ensures compliance with international quality standards.

Lipoflex Special Without Electrolytes is employed in parenteral nutrition to deliver essential amino acids for patients unable to receive enteral feeding.

Parenteral nutrition for patients unable to receive enteral nutrition: provides essential amino acids to meet metabolic requirements. Postoperative patients: supports recovery by supplying amino acids for tissue repair and protein synthesis. Critical care patients: maintains nitrogen balance and supports organ function during intensive therapy. Severe burns: supplies amino acids needed for wound healing and protein turnover.

Lipoflex Special Without Electrolytes may be associated with the following adverse reactions observed in clinical use.

Common Side Effects: - Hyperglycemia: elevated blood glucose levels during infusion. - Phlebitis: irritation or inflammation at the infusion site. - Mild electrolyte shifts: transient changes despite the product being electrolyte‑free. - Infusion‑related rash: localized skin reaction.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical intervention. - Metabolic acidosis: significant acid‑base disturbance. - Severe hyperammonemia: elevated ammonia levels, particularly in patients with hepatic impairment.

When using Lipoflex Special Without Electrolytes, clinicians should consider the following precautions.

Renal impairment: adjust infusion rate and monitor renal function. Hepatic dysfunction: monitor ammonia and liver enzymes. Inborn errors of amino‑acid metabolism: avoid in patients with known metabolic disorders. Pregnancy and lactation: use only if potential benefit outweighs risk. Monitoring: regularly assess plasma amino‑acid concentrations and metabolic parameters. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Potential drug interactions should be reviewed before initiating therapy.

Major Interactions (Avoid): - Concurrent high‑dose amino‑acid solutions: risk of amino‑acid overload. - Renal replacement therapy: may remove administered amino acids, reducing efficacy. - Nephrotoxic chemotherapeutic agents (e.g., methotrexate): increased risk of renal injury.

Moderate Interactions (Monitor Closely): - Insulin therapy: may require dose adjustment due to glucose fluctuations. - Loop diuretics: monitor electrolyte balance despite product being electrolyte‑free. - Corticosteroids: may increase protein catabolism, necessitating closer nutritional monitoring.